Celldex Therapeutics (CLDX) Stock

NASDAQ / Healthcare / Biotechnology

$29.87

+5.66% Close Nov 6

CLDX stock daily candlestick chart with 50, 150 and 200-day moving averagesOpen interactive chart
One year of daily prices through the Nov 6, 2026 close. This page updates by about 4 AM ET after each trading day. The interactive chart has the full history.

CLDX stock price and performance

CLDX stock closed at $29.87 on Nov 6, 2026. The tables below use that final daily session.

Last close
$29.87
Day range
$27.82 to $30.15
52-week range
$22.10 to $45.14
From 52-week high
−33.8%
Average volume (50 days)
1.5M
1 week
−0.8%
1 month
+2.0%
3 months
−30.5%
Year to date
+10.0%
1 year
+25.9%
3 years
+15.0%
5 years
−35.0%

Is CLDX stock in an uptrend?

Not yet. CLDX stock is not in an uptrend by our rules: it does not meet the Minervini Trend Template criteria and neither Daily Pivot Breakout momentum filter is active. Price is below its 200-day moving average.

Daily Pivot momentum filters
0 of 2 active
100-day ROC
−7.6% filter at 40%: off
100-day EMA slope
+10.7% filter at 25%: off
Trend state
Sideways
Minervini Trend Template
Not met on the latest scan
50-day average
Below
150-day average
Below
200-day average
Below
200-day slope (1 month)
+0.93%
ATR (14) % of price
4.63%

Momentum filters from the Daily Pivot Breakout indicator: 100-day rate of change and 100-day EMA slope, each against its minimum.

Is CLDX stock in a Stage 2 uptrend?

No. CLDX stock is in Stage 3 (topping) by our Weinstein stage analysis: its 30-week moving average has flattened after an advance.

Weinstein stage
Stage 3 (topping)
30-week SMA
$34.29
30-week slope (4 weeks)
−0.75%
Mansfield RS vs SPY
-6.51

Weinstein stage analysis uses weekly closes against the 30-week moving average and Mansfield relative strength versus SPY. See the free Stage 2 stocks screener.

CLDX support and resistance levels

LevelPriceFrom close
150-day SMA$34.40+15.2%
30-week SMA$34.29+14.8%
50-day SMA$32.93+10.2%
200-day SMA$32.74+9.6%
Daily Pivot resistance (pivot high)$30.82+3.2%
21-day EMA$29.98+0.4%
9-day EMA$29.49−1.3%
Latest Daily Pivot low$27.47−8.0%

Levels above the close act as resistance, levels below as support. Last close $29.87.

CLDX breakout and scanner signals

ScannerLast signal (free view, 5 sessions late)Past year
VCPNone in the last year0
RSI DivergenceOct 21, 20262
Weinstein Stage AnalysisSep 21, 2026184
Daily Pivot BreakoutNone in the last year0
Minervini Trend TemplateSep 14, 2026116
Episodic PivotNone in the last year0
Ichimoku TK crossSep 3, 2026 (bearish)9
9/21 EMA crossSep 1, 2026 (bearish)10
Golden / Death CrossNone in the last year0
RS RatingNone in the last year0

CLDX seasonality by month

  1. Jan+9.1%50% up
  2. Feb+1.8%48% up
  3. Mar−1.6%52% up
  4. Apr−0.8%52% up
  5. May−2.9%30% up
  6. Jun+20.3%59% up
  7. Jul−2.4%44% up
  8. Aug−2.5%44% up
  9. Sep−1.2%41% up
  10. Oct−0.9%52% up
  11. Nov+8.5%69% up
  12. Dec−1.9%46% up

Average monthly return over 26+ years of stored daily closes, and the share of years each month closed higher.

CLDX earnings history

ReportedEPS estimateEPS actualSurprise
Nov 5, 2026$-1.01$-0.96+5.0%
Aug 6, 2026$-1.06$-0.94+11.3%
May 7, 2026$-1.13$-1.18−4.4%
Feb 25, 2026$-1.00$-1.22−22.0%

CLDX bull and bear case

What looks strong

  • No strong points in the trend data on the latest scan.

What looks weak

  • Neither Daily Pivot momentum filter is active (100-day ROC -7.6%, 100-day EMA slope 10.7%; the filters need 40% and 25%).
  • Does not meet the Minervini Trend Template on the latest scan.
  • Price is below the 200-day moving average.
  • Short interest is 14.51% of shares outstanding.
  • Net income over the last 12 months is negative.

Drawn only from the data on this page. Not a recommendation.

CLDX news and SEC filings, last 30 days

Source: SEC EDGAR.

CLDX insider trading and risks

Risk flags from the data

  • Short interest is 14.51% of shares outstanding.
  • Net income over the last 12 months is negative.

Insider trades: SEC Form 4 open-market purchases and sales.

CLDX valuation and fundamentals

Market cap
$2.35B
Enterprise value
$1.71B
P/E (trailing)
-7.7
P/E (forward)
-7.1
PEG
-0.72
Price to sales
14,848.99
Price to book
3.61
EV to EBITDA
-5.2
Gross margin
–
Operating margin
−211,684.8%
Profit margin
0.0%
Return on equity
−49.5%
Revenue (TTM)
$158,000
Revenue growth (quarter, y/y)
+46.7%
Cash
$650.3M
Debt
$9.9M
Fiscal yearRevenueNet incomeFree cash flow
2025$1.5M−$258.8M−$210.9M
2024$7.0M−$157.9M−$135.7M
2023$6.9M−$141.4M−$118.2M
2022$2.4M−$112.3M−$100.0M

CLDX dividends and splits

Dividend yield
0.00%
Payout ratio
0.0%

Stock splits: 1-for-15 split on Feb 11, 2019, 1-for-12 split on Mar 10, 2008.

Who owns CLDX?

Shares outstanding
78.5M
Float
73.0M
Held by insiders
+0.3%
Held by institutions
+110.0%
Short interest (% of shares)
+14.5%
Days to cover
4.3

What does Celldex Therapeutics Inc. do?

CEO
Mr. Anthony S. Marucci M.B.A.
Employees
198
Headquarters
Hampton, NJ, United States

Updated Nov 6, 2026. Prices and fundamentals: Source: Twelve Data. Filings and insider trades: SEC EDGAR. Charts: TradingView Lightweight Charts. Educational information, not investment advice.